Table 1.
Clinical Trial Testing of NLRP3 and HSP70 Inhibitors in Oncology.
| Target | Compound Name | Trial Phase | Indication | Status | NCT Identifier |
|---|---|---|---|---|---|
| NLRP3 | Dapansutrile (OLT1177) | I/II | w/ Pembrolizumb in Anti-PD-1-Resistant Melanoma | Not Yet Recruiting |
NCT04971499 |
| Resveratrol | I | Colon cancer | Completed | NCT00256334 | |
| Resveratrol | I | Colon cancer | Completed | NCT00433576 | |
| Resveratrol | I | Colon Cancer | Completed | NCT00920803 | |
| HSP70 | Minnelide | I | Advanced GI Tumors | Completed | NCT01927965 |
| Minnelide | II | Refractory Pancreatic Adenocarcinoma | Completed | NCT03117920 | |
| Minnelide | II | Refractory Pancreatic Adenosquamous carcinoma |
Recruiting | NCT04896073 | |
| Minnelide | I | Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | NCT03760523 | |
| Minnelide | I | Advanced Solid Tumors | Recruiting | NCT03129139 |